Core Viewpoint - Yunnan Watson Bio-Technology Co., Ltd. has signed an amendment to the exclusive sublicense agreement with Notitia Biotechnologies Company to expand its development and commercialization rights in the field of gut microbiota health targeting non-patient populations, aligning with national health strategies [1][2]. Group 1: Agreement Details - The amendment allows Watson Bio to exclusively develop, manufacture, and commercialize core microbiota analysis, targeted transplantation, and nutritional formula technologies in mainland China, Hong Kong, and Macau for non-patient populations [1][2]. - The agreement aims to establish a dual-track layout of "disease treatment intervention" and "chronic disease prevention + health nutrition," providing comprehensive health solutions [1][2]. - The amendment does not constitute a related party transaction or a major asset restructuring as defined by regulations [1][2]. Group 2: Financial Terms - Watson Bio will pay Notitia a total of $1,500,000 in license issue fees, with specific payment schedules outlined [3][4]. - Ongoing royalties will be 6.5% of net sales from sublicensed products, with minimum royalty payments established for subsequent years [4][5]. - Milestone payments are structured based on the achievement of specific regulatory approvals and sales targets, with amounts ranging from $500,000 to $30,500,000 [5][6]. Group 3: Company Impact - The signing of the amendment is not expected to significantly impact the company's operating performance for the current year, as the financial arrangements are closely tied to product development progress [6]. - The payment structure is designed to ensure efficient use of funds and alleviate short-term financial burdens on the company [6].

Core Viewpoint - Watson Bio (300142.SZ) has signed an amendment to its exclusive sublicense agreement with Notitia Biotechnologies Company to enhance its market competitiveness and expand its core microbiome therapy in the field of precise micro-ecological health and functional nutrition intervention [1] Group 1: Agreement Details - The amendment allows Watson Bio to exclusively develop, manufacture, and commercialize core microbiome analysis, microbiome-targeted transplantation, and nutritional formula technologies in mainland China, Hong Kong, and Macau for non-patient populations [1] - This agreement is based on the upstream licensing agreement that Notitia has with Rutgers University in New Jersey, USA [1] Group 2: Strategic Implications - The signing of this amendment signifies a dual-track layout for the company, combining "disease treatment intervention" with "chronic disease prevention and health nutrition" [1] - The initiative aligns with national policies on non-drug interventions and emphasizes the importance of chronic disease nutrition and prevention strategies [1] Group 3: Market Positioning - The company aims to provide a comprehensive health solution that covers in-hospital treatment, out-of-hospital management, and multi-scenario interventions [1] - This move is expected to integrate existing clinical pathways and underlying technology platform construction, offering diverse product forms to address sub-health and high-risk chronic disease populations [1]